Delivery Order SPE2DR25D2011-SPE2DR26FADWU
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,476.11 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25, a combination inhalation powder used to treat chronic obstructive pulmonary disease. The award was issued on January 13, 2026, with an ultimate completion date of January 14, 2026, and utilized firm fixed-price pricing with no set-aside designation. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's...
- The Defense Logistics Agency awarded a $6,871.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 15, 2026, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder, a combination respiratory medication used to treat chronic obstructive pulmonary disease. This non-set-aside, competitively awarded delivery order is scheduled for completion by January 16, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $55,290.76 delivery order to AmerisourceBergen Drug Corp on December 17, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder in 60-dose units. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $14,398.07 to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder in a 60-dose configuration. This competitive, firm fixed-price delivery order has an ultimate completion date of January 30, 2026, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a task order execution under the company's larger...
- The Defense Logistics Agency awarded a delivery order valued at $9,762.73 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalation powder, a combination respiratory medication used to treat chronic obstructive pulmonary disease. The contract, issued on January 13, 2026, with an ultimate completion date of January 14, 2026, represents a firm fixed-price purchase under a non-competed delivery order structure. The awardee, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $8,702.52 to AmerisourceBergen Drug Corp on January 6, 2026, for the supply of Trelegy Ellipta 200-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by January 7, 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $35,272.88 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The contract is a firm fixed price delivery order with no set-aside designation, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $37,793.70 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used in respiratory disease management. This firm fixed-price, non-set-aside contract was awarded on January 30, 2026, with an ultimate completion date of February 2, 2026. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.67 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This competitively awarded, firm fixed-price delivery order is set to be completed by August 26, 2025, just one day after the award date of August 25, 2025. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,331.47 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 (60-count inhalers), a combination respiratory medication used to treat chronic obstructive pulmonary disease. This non-competitive delivery order, issued on November 10, 2025, with completion expected by November 12, 2025, represents a firm fixed-price pharmaceutical supply transaction. The award was fulfilled from AmerisourceBergen's place of performance in...
- SPE2DR25D2011Indefinite Delivery Contract
- SPE2DR25D2011-SPE2DR26FADWUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $76,221.78 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalation powder, a combination respiratory medication used to treat chronic obstructive pulmonary disease. The award was made on January 30, 2026, with an ultimate completion date of February 2, 2026, and utilized firm fixed-price pricing with no small business set-aside. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery order is a child contract under AmerisourceBergen's parent company, Cencora, Inc., which operates the entity under the AmerisourceBergen doing-business-as name. This delivery order was executed under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to military healthcare programs, the Defense Health Agency, and other federal medical institutions worldwide. The competitively awarded delivery order reflects the company's established capability to efficiently fulfill government pharmaceutical procurement requirements across multiple therapeutic domains supporting military and veteran healthcare systems.